Viking Therapeutics Reports Q3 GAAP EPS of -$1.55, Missing Estimates by $0.50
Viking Therapeutics (VKTX) reported third-quarter GAAP earnings per share of -$1.55, missing analyst expectations by $0.50. The miss highlights the ongoing heavy research and development spending characteristic of clinical-stage biotechnology firms. Despite the earnings miss, the company is focusing on its lead candidate, VK2735, for obesity and type 2 diabetes treatment. Recent discussions have centered on top-line data from maintenance studies, which aim to establish weight loss maintenance as a significant future growth driver for the firm.